Background:Thepresenceofco-morbidities,includingunderlyingrespiratoryproblems,hasbeenidenti-fiedasariskfactorforsevereCOVID-19disease.InformationontheclinicalcourseofSARS-CoV-2infec-tioninchildrenwithcysticfibrosis(CF)islimited,yetvitaltoprovideaccurateadviceforchildrenwithCF,theirfamilies,caregiversandclinicalteams.Methods:CasesofSARS-CoV-2infectioninchildrenwithCFagedlessthan18yearswerecollatedbytheCFRegistryGlobalHarmonizationGroupacross13countriesbetween1Februaryand7August2020.Results:Dataon105childrenwerecollatedandanalysed.Medianageofcaseswastenyears(interquar-tilerange6–15),54%weremaleandmedianpercentagepredictedforcedexpiratoryvolumeinonesecond was94%(interquartilerange79–104).Themajority(71%)ofchildrenweremanagedinthecommunityduringtheirCOVID-19illness.Outof24childrenadmittedtohospital,sixrequiredsupplementaryoxygenandtwonon-invasiveventilation.Aroundhalfwereprescribedantibiotics,fivechildrenreceivedantivi-raltreatments,fourazithromycinandoneadditionalcorticosteroids.ChildrenthatwerehospitalisedhadlowerlungfunctionandreducedbodymassindexZ-scores.Onechilddiedsixweeksaftertestingposi-tiveforSARS-CoV-2followingadeteriorationthatwasnotattributedtoCOVID-19disease. Conclusions:SARS-CoV-2infectioninchildrenwithCFisusuallyassociatedwithamildillnessinthosewhodonothavepre-existingseverelungdisease
Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study / R. Bain, R. Cosgriff, M. Zampoli, A. Elbert, P. Burgel, S.B. Carr, C. Castaños, C. Colombo, H. Corvol, A. Faro, C.H. Goss, H. Gutierrez, A. Jung, N. Kashirskaya, B.C. Marshall, J. Melo, P. Mondejar-Lopez, I. de Monestrol, L. Naehrlich, M.D. Pastor-Vivero, S. Rizvi, L.V.R.F.d.S. Filho, K.G. Brownlee, I.J. Haq, M. Brodlie. - In: JOURNAL OF CYSTIC FIBROSIS. - ISSN 1569-1993. - 20:1(2021), pp. 25-30. [10.1016/j.jcf.2020.11.021]
Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study
C. Colombo;
2021
Abstract
Background:Thepresenceofco-morbidities,includingunderlyingrespiratoryproblems,hasbeenidenti-fiedasariskfactorforsevereCOVID-19disease.InformationontheclinicalcourseofSARS-CoV-2infec-tioninchildrenwithcysticfibrosis(CF)islimited,yetvitaltoprovideaccurateadviceforchildrenwithCF,theirfamilies,caregiversandclinicalteams.Methods:CasesofSARS-CoV-2infectioninchildrenwithCFagedlessthan18yearswerecollatedbytheCFRegistryGlobalHarmonizationGroupacross13countriesbetween1Februaryand7August2020.Results:Dataon105childrenwerecollatedandanalysed.Medianageofcaseswastenyears(interquar-tilerange6–15),54%weremaleandmedianpercentagepredictedforcedexpiratoryvolumeinonesecond was94%(interquartilerange79–104).Themajority(71%)ofchildrenweremanagedinthecommunityduringtheirCOVID-19illness.Outof24childrenadmittedtohospital,sixrequiredsupplementaryoxygenandtwonon-invasiveventilation.Aroundhalfwereprescribedantibiotics,fivechildrenreceivedantivi-raltreatments,fourazithromycinandoneadditionalcorticosteroids.ChildrenthatwerehospitalisedhadlowerlungfunctionandreducedbodymassindexZ-scores.Onechilddiedsixweeksaftertestingposi-tiveforSARS-CoV-2followingadeteriorationthatwasnotattributedtoCOVID-19disease. Conclusions:SARS-CoV-2infectioninchildrenwithCFisusuallyassociatedwithamildillnessinthosewhodonothavepre-existingseverelungdisease
| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS1569199320309310.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
399.6 kB
Formato
Adobe PDF
|
399.6 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
